Literature DB >> 11505128

Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients.

B R Gordon1, T S Parker, D M Levine, S D Saal, J C Wang, B J Sloan, P S Barie, A L Rubin.   

Abstract

OBJECTIVE: To determine the relationship of hypolipidemia to cytokine concentrations and clinical outcomes in critically ill surgical patients.
DESIGN: Consecutive, prospective case series.
SETTING: Surgical intensive care unit of an urban university hospital. PATIENTS: Subjects were 111 patients with a variety of critical illnesses, for whom serum lipid, lipoprotein, and cytokine concentrations were determined within 24 hrs of admission to a surgical intensive care unit. Controls were 32 healthy men and women for whom serum lipid, lipoprotein, and cytokine concentrations were determined.
INTERVENTIONS: Blood samples were drawn on admission to the intensive care unit. Predetermined clinical outcomes including death, infection subsequent to intensive care unit admission, length of intensive care unit stay, and magnitude of organ dysfunction were monitored prospectively.
MEASUREMENTS AND MAIN RESULTS: Measurements included total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoproteins A-I and B, phospholipid, triglyceride, interleukin-6, interleukin-10, soluble interleukin-2 receptor, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptors p55 and p75. Mean serum lipid concentrations were extremely low: total cholesterol, 127 +/- 52 mg/dL; low-density lipoprotein cholesterol, 75 +/- 41 mg/dL; high-density lipoprotein cholesterol, 29 +/- 15 mg/dL. Total, low-density lipoprotein, and high-density lipoprotein cholesterol concentrations and apolipoprotein concentrations inversely correlated with interleukin-6, soluble interleukin-2 receptor, and interleukin-10 concentrations, whereas the triglyceride concentration correlated positively with tumor necrosis factor soluble receptors p55 and p75. Clinical outcomes were related to whether the admission cholesterol concentration was above (n = 56) or below (n = 55) the median concentration of 120 mg/dL. Each of the clinical end points occurred between 1.9- and 3.5-fold more frequently in the very low cholesterol (<120 mg/dL) group. Nine patients (8%) died during the hospitalization. Seven of the nine patients who died had total cholesterol concentrations below the median concentration of 120 mg/dL.
CONCLUSIONS: Low cholesterol and lipoprotein concentrations found in critically ill surgical patients correlate with interleukin-6, soluble interleukin-2 receptor, and interleukin-10 concentrations and predict clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505128     DOI: 10.1097/00003246-200108000-00011

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  45 in total

1.  Adrenal-exhaustion syndrome in patients with liver disease.

Authors:  Paul E Marik
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

2.  Cholesterol metabolism in active Crohn's disease.

Authors:  Vladimír Hrabovský; Zdenek Zadák; Vladimír Bláha; Radomír Hyspler; Tomás Karlík; Arnost Martínek; Alice Mendlová
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Changes in cholesterol level correlate with the course of pulmonary nontuberculous mycobacterial disease.

Authors:  Ji Young Hong; Go Eun Yang; Yousang Ko; Yong Bum Park; Yun Su Sim; Sung Hoon Park; Chang Youl Lee; Ki-Suck Jung; Myung Goo Lee
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

4.  Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit.

Authors:  Megumi Shimizu; Tetsuro Miyazaki; Atsutoshi Takagi; Yurina Sugita; Shoichiro Yatsu; Azusa Murata; Takao Kato; Shoko Suda; Shohei Ouchi; Tatsuro Aikawa; Masaru Hiki; Shuhei Takahashi; Makoto Hiki; Hidemori Hayashi; Takatoshi Kasai; Kazunori Shimada; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2016-12-09       Impact factor: 2.037

5.  Critical illness is associated with decreased plasma levels of coenzyme Q10: a cross-sectional study.

Authors:  Andrea Coppadoro; Lorenzo Berra; Asheesh Kumar; Riccardo Pinciroli; Marina Yamada; Ulrich H Schmidt; Edward A Bittner; Masao Kaneki
Journal:  J Crit Care       Date:  2013-04-22       Impact factor: 3.425

6.  Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator.

Authors:  Amelia K Boehme; Niren Kapoor; Karen C Albright; Michael J Lyerly; Pawan V Rawal; Reza Bavarsad Shahripour; Muhammad Alvi; J Thomas Houston; April Sisson; T Mark Beasley; Anne W Alexandrov; Andrei V Alexandrov; David W Miller
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-01-11       Impact factor: 2.136

7.  Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella.

Authors:  F Apostolou; I F Gazi; A Kostoula; C C Tellis; A D Tselepis; M Elisaf; E N Liberopoulos
Journal:  J Lipid Res       Date:  2009-06-17       Impact factor: 5.922

8.  Low HDL levels and the risk of death, sepsis and malignancy.

Authors:  Renana Shor; Julio Wainstein; David Oz; Mona Boaz; Zipora Matas; Asora Fux; Aaron Halabe
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

9.  Changes in plasma LDL and HDL composition in patients undergoing cardiac surgery.

Authors:  M Hacquebard; A Ducart; D Schmartz; W J Malaisse; Y A Carpentier
Journal:  Lipids       Date:  2007-10-03       Impact factor: 1.880

10.  Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin.

Authors:  Lucie Vavrova; Jana Rychlikova; Magdalena Mrackova; Olga Novakova; Ales Zak; Frantisek Novak
Journal:  Clin Exp Med       Date:  2015-09-28       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.